Basal Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major basal cell carcinoma markets reached a value of US$ 5.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 9.3 Billion by 2034, exhibiting a growth rate (CAGR) of 5.31% during 2024-2034.
The basal cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Basal Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Basal cell carcinoma (BCC) refers to a non-melanocytic skin cancer that arises from basal cells located in the lower layer of the epidermis. It is often characterized by a painless raised area of skin, which may be shiny with ulcerations or tiny blood vessels running over it. BCC is an aggressive illness that can destroy the tissues around it, causing severe complications like disfigurement. The common symptoms associated with this disease include skin lesions, redness, a small bump, loss of color, scaly patches, swollen blood vessels in the skin, nodules, a waxy, hard skin growth, etc. In some cases, patients also experience itchiness and oozing. The diagnosis of BCC is typically made by reviewing the patient's symptoms, medical history, and physical tests. Further, a skin biopsy, which involves the removal of tiny samples of the affected skin lesion to examine it under a high-powered microscope, is required to confirm a diagnosis. The healthcare provider may also perform a CT or MRI scan to visualize cancer in the lymph nodes or internal organs.
The increasing cases of overexposure to ultraviolet rays from the sun that can damage DNA in the skin cells are primarily driving the basal cell carcinoma market. In addition to this, the rising incidences of several associated risk factors, including advancing age, fairer skin, chronic infections, family history of cancer, etc., are also bolstering the market growth. Furthermore, the widespread adoption of hedgehog pathway inhibitors, such as sonidegib and vismodegib, for treating locally advanced or metastatic disease conditions is acting as another significant growth-inducing factor. These medications inhibit a transmembrane protein required for Hedgehog signal transduction, thereby restricting tumor growth and preventing its recurrence in patients. Additionally, the escalating demand for cryotherapy, which uses liquid nitrogen to freeze and destroy tumor cells and ultimately improve overall survival, is further creating a positive outlook for the market. Apart from this, the emerging popularity of programmed death receptor-1 blocking antibodies, including cemiplimab, over traditional treatment options on account of their improved efficacy and safety profiles is expected to drive the basal cell carcinoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the basal cell carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for basal cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the basal cell carcinoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the basal cell carcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the basal cell carcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current basal cell carcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the basal cell carcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the basal cell carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the basal cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of basal cell carcinoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of basal cell carcinoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of basal cell carcinoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with basal cell carcinoma across the seven major markets?
What is the size of the basal cell carcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of basal cell carcinoma?
What will be the growth rate of patients across the seven major markets?
Basal Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for basal cell carcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the basal cell carcinoma market?
What are the key regulatory events related to the basal cell carcinoma market?
What is the structure of clinical trial landscape by status related to the basal cell carcinoma market?
What is the structure of clinical trial landscape by phase related to the basal cell carcinoma market?
What is the structure of clinical trial landscape by route of administration related to the basal cell carcinoma market?
The basal cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Basal Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Basal cell carcinoma (BCC) refers to a non-melanocytic skin cancer that arises from basal cells located in the lower layer of the epidermis. It is often characterized by a painless raised area of skin, which may be shiny with ulcerations or tiny blood vessels running over it. BCC is an aggressive illness that can destroy the tissues around it, causing severe complications like disfigurement. The common symptoms associated with this disease include skin lesions, redness, a small bump, loss of color, scaly patches, swollen blood vessels in the skin, nodules, a waxy, hard skin growth, etc. In some cases, patients also experience itchiness and oozing. The diagnosis of BCC is typically made by reviewing the patient's symptoms, medical history, and physical tests. Further, a skin biopsy, which involves the removal of tiny samples of the affected skin lesion to examine it under a high-powered microscope, is required to confirm a diagnosis. The healthcare provider may also perform a CT or MRI scan to visualize cancer in the lymph nodes or internal organs.
The increasing cases of overexposure to ultraviolet rays from the sun that can damage DNA in the skin cells are primarily driving the basal cell carcinoma market. In addition to this, the rising incidences of several associated risk factors, including advancing age, fairer skin, chronic infections, family history of cancer, etc., are also bolstering the market growth. Furthermore, the widespread adoption of hedgehog pathway inhibitors, such as sonidegib and vismodegib, for treating locally advanced or metastatic disease conditions is acting as another significant growth-inducing factor. These medications inhibit a transmembrane protein required for Hedgehog signal transduction, thereby restricting tumor growth and preventing its recurrence in patients. Additionally, the escalating demand for cryotherapy, which uses liquid nitrogen to freeze and destroy tumor cells and ultimately improve overall survival, is further creating a positive outlook for the market. Apart from this, the emerging popularity of programmed death receptor-1 blocking antibodies, including cemiplimab, over traditional treatment options on account of their improved efficacy and safety profiles is expected to drive the basal cell carcinoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the basal cell carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for basal cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the basal cell carcinoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the basal cell carcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the basal cell carcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current basal cell carcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the basal cell carcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the basal cell carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the basal cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of basal cell carcinoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of basal cell carcinoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of basal cell carcinoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with basal cell carcinoma across the seven major markets?
What is the size of the basal cell carcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of basal cell carcinoma?
What will be the growth rate of patients across the seven major markets?
Basal Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for basal cell carcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the basal cell carcinoma market?
What are the key regulatory events related to the basal cell carcinoma market?
What is the structure of clinical trial landscape by status related to the basal cell carcinoma market?
What is the structure of clinical trial landscape by phase related to the basal cell carcinoma market?
What is the structure of clinical trial landscape by route of administration related to the basal cell carcinoma market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BASAL CELL CARCINOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BASAL CELL CARCINOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BASAL CELL CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BASAL CELL CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BASAL CELL CARCINOMA - UNMET NEEDS
10 BASAL CELL CARCINOMA - KEY ENDPOINTS OF TREATMENT
11 BASAL CELL CARCINOMA - MARKETED PRODUCTS
11.1 List of Basal Cell Carcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Aldara (Imiquimod) - 3M Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Libtayo (Cemiplimab) - Regeneron Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Erivedge (Vismodegib) - Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Odomzo (Sonidegib) - Sun Pharmaceutical Industries
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BASAL CELL CARCINOMA - PIPELINE DRUGS
12.1 List of Basal Cell Carcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 EscharEx - MediWound
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AIV 001 - AiViva BioPharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 STP705 - Sirnaomics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Patidegib - Sol-Gel Technologies
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 LTX315 - Verrica Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BASAL CELL CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BASAL CELL CARCINOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BASAL CELL CARCINOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Basal Cell Carcinoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Basal Cell Carcinoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Basal Cell Carcinoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Basal Cell Carcinoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Basal Cell Carcinoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Basal Cell Carcinoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Basal Cell Carcinoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Basal Cell Carcinoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Basal Cell Carcinoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Basal Cell Carcinoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Basal Cell Carcinoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Basal Cell Carcinoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Basal Cell Carcinoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Basal Cell Carcinoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Basal Cell Carcinoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Basal Cell Carcinoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Basal Cell Carcinoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Basal Cell Carcinoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Basal Cell Carcinoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Basal Cell Carcinoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Basal Cell Carcinoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Basal Cell Carcinoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Basal Cell Carcinoma - Access and Reimbursement Overview
16 BASAL CELL CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BASAL CELL CARCINOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BASAL CELL CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BASAL CELL CARCINOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BASAL CELL CARCINOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BASAL CELL CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BASAL CELL CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BASAL CELL CARCINOMA - UNMET NEEDS
10 BASAL CELL CARCINOMA - KEY ENDPOINTS OF TREATMENT
11 BASAL CELL CARCINOMA - MARKETED PRODUCTS
11.1 List of Basal Cell Carcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Aldara (Imiquimod) - 3M Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Libtayo (Cemiplimab) - Regeneron Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Erivedge (Vismodegib) - Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Odomzo (Sonidegib) - Sun Pharmaceutical Industries
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BASAL CELL CARCINOMA - PIPELINE DRUGS
12.1 List of Basal Cell Carcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 EscharEx - MediWound
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AIV 001 - AiViva BioPharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 STP705 - Sirnaomics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Patidegib - Sol-Gel Technologies
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 LTX315 - Verrica Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BASAL CELL CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BASAL CELL CARCINOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BASAL CELL CARCINOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Basal Cell Carcinoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Basal Cell Carcinoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Basal Cell Carcinoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Basal Cell Carcinoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Basal Cell Carcinoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Basal Cell Carcinoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Basal Cell Carcinoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Basal Cell Carcinoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Basal Cell Carcinoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Basal Cell Carcinoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Basal Cell Carcinoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Basal Cell Carcinoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Basal Cell Carcinoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Basal Cell Carcinoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Basal Cell Carcinoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Basal Cell Carcinoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Basal Cell Carcinoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Basal Cell Carcinoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Basal Cell Carcinoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Basal Cell Carcinoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Basal Cell Carcinoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Basal Cell Carcinoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Basal Cell Carcinoma - Access and Reimbursement Overview
16 BASAL CELL CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BASAL CELL CARCINOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BASAL CELL CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
